AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02194829
Drug: AZD1775
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02325583
Drug: 30% Glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORAL 30% GLUCOSE 0,5-2 ML
Trial: NCT00600847
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose for 7 days, oral
Trial: NCT04071171
Drug: CVVH with Phoxilium® in the first 48h after randomization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After randomization into the Phoxilium®-group, CVVH will be initiated with Phoxilium® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
Trial: NCT01741389
Drug: Melatonin (Circadin)
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00636480
Drug: ChloraPrep One Step
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer topically
Trial: NCT00636480
Drug: Sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl solution
Trial: NCT04415645
Drug: [14C]-VVZ-149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single IV infusion of radio-labeled VVZ-149
Trial: NCT00561717
Drug: Placebo and Placebo (spray and Tablet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
Trial: NCT01921907
Drug: AD17137 topical treatment
RxNorm normalized name: Acne Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01921907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04071171
Drug: CVVH with Biphozyl® in the first 48h after randomization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After randomization into the Biphozyl®-group, CVVH will be initiated with Biphozyl® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
Trial: NCT01010204
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
Trial: NCT03204500
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally under the same conditions
Trial: NCT03186586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo one pill a day for 5 days at the bleeding episode
Trial: NCT03598699
Drug: AXR-159
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXR-159 Ophthalmic Solution
Trial: NCT03598699
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXR-159 Ophthalmic Solution Vehicle
Trial: NCT04486313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo tablets administered orally twice daily with food for 5 days
Trial: NCT04071171
Drug: CVVH with Phoxilium® in the second 48h after randomization (after previous 48h with Biphozyl®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48h post randomization, respectively after the cross-over CVVH will be continued with Phoxilium® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
Trial: NCT04071171
Drug: CVVH with Biphozyl® in the second 48h after randomization (after previous 48h with Phoxilium®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48h post randomization, respectively after the cross-over CVVH will be continued with Biphozyl® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
Trial: NCT02609152
Drug: Continuous perfusion of saline
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the control arm of the study, a continuous infusion of normal saline will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. A H4, the doctor in charge is free to gradually continue or stop the infusion.
Trial: NCT01159483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT00037115
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03752242
Drug: BMX-010 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and efficacy of BMX-010 in topical treatment of acne.
Trial: NCT00307164
Drug: NucleomaxX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 g sachet taken orally three times daily
Trial: NCT00307164
Drug: NucleomaxX placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 g placebo sachet taken orally three times daily
Trial: NCT02020746
Drug: EscharEx
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02543099
Drug: policosanol
RxNorm normalized name: POLICOSANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive policosanol 20mg Qd
Trial: NCT02543099
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo 20mg Qd;
Trial: NCT01496365
Drug: DS-5565 tablet
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg and 10mg tablets
Trial: NCT01496365
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01496365
Drug: placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03017547
Drug: IC14
RxNorm normalized name: CATH,INTERMIT 14FR RELIAMED #PIC1416
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blocks CD14 signalling which is responsible for disease pathogenesis in ARDS
Trial: NCT00469456
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral administration twice daily for 12 weeks
Trial: NCT00135577
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00408798
Drug: Intracutaneous injections of Botulinum Toxin A (Botox), 0.1 cc per injection site, which equals 10 units
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Detailed Description.
Trial: NCT00855049
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal acetaminophen administration
Trial: NCT02578914
Drug: NS2 Ophthalmic Drops Vehicle (0.0%)
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00855049
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen administration
Trial: NCT00813098
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo dosing with daily oral intake
Trial: NCT00766402
Drug: Tramadol /acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a combination tablet of 37.5 milligram (mg) tramadol and 325 mg acetaminophen, orally twice daily up to 8 weeks.
Trial: NCT00766402
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive 50 mg diclofenac tablet, orally twice daily up to 8 weeks.
Trial: NCT03626831
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of placebo
Trial: NCT02367105
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily testosterone gel applied once daily in the morning to intact skin
Trial: NCT02367105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel for testosterone
Trial: NCT02560389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill packaged to resemble levodopa
Trial: NCT02560389
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.
Trial: NCT01377168
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02547441
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Gel
Trial: NCT02025855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00024128
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02949232
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prednisolone will be will be initiated during the first week at 40mg/day for 3 days and 30mg/day for 4 days, followed by a decrease of 5mg/day per week during the remaining 5 weeks; in the second week, patients will use 25 mg/day, in the third week 20 mg/day is used etc. In the last week the patients will only take prednisolone on day 1-3 and day 5 and 7; a tapering scheme in line with the treatment guidelines for Inflammatory Bowel Diseases (2008).
Trial: NCT02949232
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing following the tapering scheme of the treatment of the treatment arm
Trial: NCT02987998
Drug: Radiation
RxNorm normalized name: Miaderm Radiation Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation (1.8Gy/D to 45Gy in 25 fractions)
Trial: NCT03317028
Drug: CS02 tablet and placebo tablet
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.
Trial: NCT02500914
Drug: SC-002
RxNorm normalized name: heparinoids 0.002 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks
Trial: NCT02980705
Drug: SUNPG1622 I dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT02980705
Drug: Placebo dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT01302938
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo of Tolterodine ER 4 mg will be taken with water every day with or without food. It should be swallowed whole without chewing.
Trial: NCT02562144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cutaneous placebo before intravenous cannulation.
Trial: NCT02039544
Drug: Xuebi formula
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02039544
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00444262
Drug: VOLUVEN and others solute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VOLUVEN and others solute
Trial: NCT02530788
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the evening before operation the patient receives the first dosage of placebo orally as a pill.~After induction of anaesthesia and before being put on the heart-lung-machine the patient receives placebo intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets placebo intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives placebo intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD).
Trial: NCT00947323
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 20 daily for six months.
Trial: NCT00947323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00446940
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04429802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered
Trial: NCT01472614
Drug: DLBS3233
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study treatment will be DLBS3233 at a dose of 100 mg once daily (for 12 weeks) in addition to current anti-diabetic treatment used by respective study subjects and treatment intensification (lifestyle modification)
Trial: NCT00005824
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03625453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: 8 weeks with daily administration
Trial: NCT01773876
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution of sodium chloride 0.9% 100 ml for intravenous infusion infusion over 24 hours for 14 days discontinuation of placebo if proven invasive candidiasis
Trial: NCT01413022
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01413022
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02353871
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A solution containing only the excipients of BTX-A-HAC NG (identical in appearance to the active product). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
Trial: NCT00841230
Drug: Lactose placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose used as placebo
Trial: NCT01278108
Drug: GLPG0778
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single ascending doses, oral solution (10 to 800 mg/dose) and capsules (100 mg/dose)
Trial: NCT01278108
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, oral solution or capsule (matching corresponding study medication)
Trial: NCT01278108
Drug: GLPG0778
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, capsule, 7 days
Trial: NCT01278108
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, capsule, 7 days
Trial: NCT00456417
Drug: 123-I MNI-187 Injection and Imaging Procedures
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02690337
Drug: DS-1123
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: starting intravenous (IV) dose of 0.1 mg/kg.
Trial: NCT04631588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) injection
Trial: NCT02140346
Drug: RV1729 matching placebo 28 day repeat dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of repeat doses
Trial: NCT00136682
Drug: patient-controlled intravenous analgesia (PCA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.
Trial: NCT03289481
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet
Trial: NCT03935217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Granules of placebo manufactured to mimic secnidazole
Trial: NCT02311088
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02311088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02037776
Drug: Rikkunshito
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Oral administration of rikkunshito (2.5 g t.i.d) before meals for 8 weeks
Trial: NCT02037776
Drug: Rikkunshito placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Oral administration of rikkunshito placebo (2.5 g t.i.d) before meals for 8 weeks
Trial: NCT00503607
Drug: BLI-800
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002722
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002722
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03774290
Drug: PBF-680
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBF-680 is an adenosine A1 receptor antagonist
Trial: NCT03774290
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral gelatine capsule
Trial: NCT02783820
Drug: MMV390048 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02783820
Drug: Placebo to match MMV390048 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02783820
Drug: MMV390048 80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02783820
Drug: Placebo to match MMV390048 80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02783820
Drug: MMV390048 120 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01265641
Drug: AZD1981, 2000mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose, tablets
Trial: NCT01265641
Drug: AZD1981, 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose, tablets
Trial: NCT01265641
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose, tablets
Trial: NCT02936037
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an inactive substance
Trial: NCT01488955
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg oral once a day from day 0 for 3 days
Trial: NCT00303927
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00730015
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, once daily
Trial: NCT01821430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group will follow the same titration as the pregabalin group
Trial: NCT00517842
Drug: ViNeuro
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00522743
Drug: growth hormone and gonadotropin-releasing hormone agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH \& GNRHa treatment
Trial: NCT01854736
Drug: Grazax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRAZAX
Trial: NCT01347671
Drug: GRT6005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25µg/day once daily
Trial: NCT01347671
Drug: GRT6005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 µg/day once daily
Trial: NCT01347671
Drug: GRT6005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 µg/day once daily
Trial: NCT01347671
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT00517049
Drug: PRO95780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00385099
Drug: GW876008
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03831854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of oral Placebo
Trial: NCT02438371
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03546816
Drug: Placebo Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablets
Trial: NCT03169192
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intravenous injections once every 3 months
Trial: NCT00285181
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04213677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo po qd. Additionally, participants will receive lifestyle modification and nutrition education.